Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 3/20 | 0.66 |
| ▸ | JAK3 | P52333 | 3/20 | 0.66 |
| ▸ | JAK2 | O60674 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | BRD4 | O60885 | 15/20 | 0.53 |
| ▸ | CTSC | P53634 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL341837 | 1.00 | JAK1 (0.66) | JAK1JAK3JAK2CYP3A4BRD4 | |
| SCHEMBL340057 | 0.90 | CTSC (0.54) | JAK1JAK3JAK2CYP3A4BRD4 | |
| SCHEMBL29610461 | 0.90 | CTSC (0.54) | JAK1JAK3JAK2CYP3A4BRD4 | |
| SCHEMBL17060804 | 0.85 | JAK1 (0.69) | JAK1JAK3JAK2CYP3A4BRD4 | |
| SCHEMBL341215 | 0.85 | JAK1 (0.72) | JAK1JAK3JAK2CYP3A4BRD4 | |
| SCHEMBL29609910 | 0.85 | JAK1 (0.72) | JAK1JAK3JAK2CYP3A4BRD4 | |
| SCHEMBL29610195 | 0.82 | JAK1 (0.75) | JAK1JAK3JAK2CYP3A4BRD4 | |
| SCHEMBL341397 | 0.82 | JAK1 (0.75) | JAK1JAK3JAK2CYP3A4BRD4 | |
| SCHEMBL15391690 | 0.82 | JAK2 (0.64) | JAK1JAK3JAK2CYP3A4BRD4 | |
| SCHEMBL341129 | 0.81 | JAK1 (0.68) | JAK1JAK3JAK2CYP3A4BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4009974-A1 | COMPOUNDS AND METHOD FOR TREATING CYTOKINE RELEASE SYNDROME | Rigel Pharmaceuticals, Inc. (US) | 2022-06-15 | — | — | EP | disclosed |